What is Rhaeos?
Rhaeos, Inc. is a private, clinical stage medical device company that emerged from Northwestern University's John A. Rogers Research Group. The company is dedicated to developing wearable sensors designed to enhance the care of patients managing chronic and complex conditions. Its flagship product, the FlowSense noninvasive wireless sensor, aims to address a critical unmet need in the management of hydrocephalus. The company's development has been supported by grants from prestigious institutions such as the National Institute of Health and the National Science Foundation, alongside backing from various pediatric foundations and accelerators.
How much funding has Rhaeos raised?
Rhaeos has raised a total of $12.7M across 2 funding rounds:
Angel/Seed
$2.2M
Series A
$10.5M
Angel/Seed (2021): $2.2M with participation from Creative Ventures, Portal Innovations, and Lateral Capital
Series A (2023): $10.5M led by Creative Ventures, Steele Foundation for Hope, and Lateral Capital
Key Investors in Rhaeos
Creative Ventures
Creative Ventures is a venture capital firm employing a method-driven approach to identify and fund companies addressing critical global challenges with deployable solutions. They focus on scalable technologies with existing market demand, mitigating risks through a market-first strategy.
Lateral Capital
Lateral Capital is a mission-driven venture fund that partners with entrepreneurs building essential digital infrastructure in Africa. They provide flexible and patient capital, investing from Seed to Growth stages with a combination of debt and equity.
Portal Innovations
Portal Innovations is a venture development engine and life sciences venture capital firm specializing in early-stage biotech and medtech startups. They offer crafted capital, lab spaces, and strategic funding to accelerate company growth.
What's next for Rhaeos?
The recent major strategic investment in Rhaeos signals a pivotal moment for the company, likely enabling it to accelerate its clinical development pipeline and scale its operations. This substantial backing, contextualized within its enterprise-level funding history, suggests Rhaeos is poised for significant growth and market penetration. The company is expected to focus on advancing its FlowSense technology through further clinical trials and preparing for commercialization, leveraging this capital to solidify its position in the medical device sector.
See full Rhaeos company page
